|
| Press Releases |
|
 |
|
| Friday, March 28, 2025 |
|
|
Hua Medicine Announces 2024 Annual Results |
| Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announced the audited full-year results of the Company and its subsidiaries for the year ended December 31, 2024 (the "Reporting Period"), along with the Company's business progress in 2024 and future business outlook. more info >> |
|
| Tuesday, March 18, 2025 |
|
|
Dr. Li Chen Honored as A Leading Figure in Shanghai's Industry and Commerce |
| On March 17th, the highly anticipated 7th Commendation and Exchange Conference for the Leading Figures in Shanghai's Industry and Commerce was brought to a successful conclusion. Dr. Li Chen, the founder and CEO of Hua Medicine, was awarded the title of "A Leading Figure in Shanghai's Industry and Commerce" for his outstanding contributions and innovative leadership in the field of biomedicine. more info >> |
|
| Monday, March 3, 2025 |
|
|
Hua Medicine Awarded Shanghai Innovative Enterprise Headquarters |
| On February 27th, the awarding ceremony of the second batch of Shanghai Innovative Enterprise Headquarters was held in Shanghai. Gong Zheng, Deputy Secretary of Shanghai Municipal Party Committee and Mayor of Shanghai, awarded the certificates to 49 innovative enterprise headquarters, and Hua Medicine was among them. more info >> |
|
| Saturday, November 30, 2024 |
|
|
Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate |
| Hua Medicine (the 'Company', HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation GKA candidate in U.S. at the 9th China BioMed Innovation and Investment Conference (CBIIC). more info >> |
|
|
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC |
| Hua Medicine (the 'Company', HKEx stock code: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism by which dorzagliatin improves the β-cell glucose sensitivity at the 9th China BioMed Innovation and Investment Conference (CBIIC). more info >> |
|
| Friday, October 25, 2024 |
|
|
Founder of Hua Medicine Dr. Chen Li was awarded the 'C.C. Tan Life Science Industrialization Award' |
| The 17th C.C. Tan Life Science Award ceremony was held at Shenyang Pharmaceutical University on October 9th. Dr. Chen Li, Founder and Chief Executive Officer of Hua Medicine, was awarded the C.C. Tan Life Science Industrialization Award . more info >> |
|
| Friday, August 30, 2024 |
|
|
Hua Medicine Announces 2024 Interim Results |
| Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2024 (the "Reporting Period"), and the Company's business progress for the first half of the year and business outlook. more info >> |
|
| Friday, August 25, 2023 |
|
|
Hua Medicine Announces 2023 Interim Results |
| First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. more info >> |
|
| Monday, October 10, 2022 |
|
|
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China |
| Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October 8th for two indications more info >> |
|
| Tuesday, June 7, 2022 |
|
|
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022 |
| Hua Medicine (the "Company", stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
CBL International Limited Announces Share Repurchase Program
Jun 4, 2025 12:00 HKT/SGT
|
|
|
Orange completes successful trial of Fujitsu 1FINITY optical transport solution
Jun 4, 2025 12:58 JST
|
|
|
LIMA'25 Wraps up with RM11 Billion in Deals and Record Global Participation 
Jun 4, 2025 11:00 HKT/SGT
|
|
|
Revigorate Announces Japan Launch, Asia Office, and New Portugal HQ
Jun 4, 2025 08:00 HKT/SGT
|
|
|
Implementation of Measures to Enhance Our Corporate Value in Connection with Toyota Industries Corporation
Jun 3, 2025 19:54 JST
|
|
|
Toyota Group to Accelerate Collaboration Towards Transforming into a Mobility Company Through Privatization of Toyota Industries Corporation
Jun 3, 2025 19:16 JST
|
|
|
Fujitsu accelerates digital transformation of financial institutions with newly systematized business strategy
Jun 3, 2025 18:46 JST
|
|
|
Fintech Forward Set to Return to Bahrain and Gather the Most Influential Leaders in Finance at its Third Edition in October 2025
Jun 3, 2025 17:45 HKT/SGT
|
|
|
Traditional Chinese Medicine Consumption Shows Promising Outlook, with Neautus's Market Leadership Becoming Increasingly Evident
Jun 3, 2025 16:56 HKT/SGT
|
|
|
Shiv Khera's New Book "Live While You're Alive" Launched in Singapore
Jun 3, 2025 15:00 HKT/SGT
|
|
|
transport logistic and HLPFI partner to launch global project cargo platform
Jun 3, 2025 14:04 HKT/SGT
|
|
|
20 Start-ups Showcase at Hong Kong Tech Pavilion in VivaTech 2025
Jun 3, 2025 11:57 HKT/SGT
|
|
|
Anime Tokyo Station Launches Official YouTube Channel
Jun 3, 2025 11:00 JST
|
|
|
Luxren Capital Introduces a New Era in Mobile Trading: Secure, Regulated, and Always at Users' Fingertips
Jun 3, 2025 05:00 HKT/SGT
|
|
|
IFEX Capital Introduces Its Latest Version of a Groundbreaking Trading Platform Connecting Traders Globally
Jun 2, 2025 22:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
